NASDAQ: MNOV · Life Sciences · 3 alerts · CIK 1226616
Share price
$1.34Close, Nov 16
Market cap
$68.7M
Shares outstanding
51.23MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Medicinova Inc filings on SEC EDGAR ↗
Jason Kruger resigned as Chief Financial Officer, principal financial officer, and principal accounting officer effective November 10, 2026. In response, the Board appointed President and CEO Yuichi Iwaki to serve as interim CFO and acting principal financial/accounting officer until a successor is named. Dr. Iwaki will not receive additional compensation for the interim role.
MediciNova reported a net loss of $7.7 million for the nine months ended September 30, 2026, an improvement from the $9.2 million loss in the prior year period. The company strengthened its liquidity by raising $6.2 million through an at-the-market equity offering, ending the quarter with $29.3 million in cash and cash equivalents.
MediciNova, Inc. entered into a first amendment to its office lease with Newport Gateway Office LLC to extend the lease term for its principal executive offices. The amendment extends the expiration date from January 31, 2027, to April 30, 2030, and includes scheduled rent increases beginning in February 2027.